Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

Company Overview

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.04 to $0.07
• 52-Week Range: $0.02 to $0.07
• Volume: 5,000 shs
• Average Volume: 109,569 shs
• Market Capitalization: $18.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Oncotelic Therapeutics Stock Analysis - MarketRank™

Oncotelic Therapeutics scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oncotelic Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncotelic Therapeutics is -4.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncotelic Therapeutics is -4.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oncotelic Therapeutics has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Oncotelic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncotelic Therapeutics has recently increased by 84.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncotelic Therapeutics does not currently pay a dividend.

Dividend Growth

Oncotelic Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the float of Oncotelic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncotelic Therapeutics has recently increased by 84.74%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Oncotelic Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncotelic Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.22% of the stock of Oncotelic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

OTLC Stock Analysis - Frequently Asked Questions

How have OTLC shares performed this year?

Oncotelic Therapeutics' stock was trading at $0.0350 at the beginning of the year. Since then, OTLC shares have increased by 34.6% and is now trading at $0.0471.
View the best growth stocks for 2025 here.

How were Oncotelic Therapeutics' earnings last quarter?

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) released its earnings results on Thursday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02.

How do I buy shares of Oncotelic Therapeutics?

Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oncotelic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncotelic Therapeutics investors own include MariMed (MRMD), First Wave BioPharma (FWBI), DSS (DSS), Cemex (CX), CohBar (CWBR), ContraFect (CFRX) and Avid Bioservices (CDMO).

Company Calendar

• Last Earnings: 8/19/2021
• Today: 7/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OTLC
• CIK: 908259
• Web: www.mateon.com
• Phone: (650) 635-7000
• Fax: 650-635-7001
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -14.16%
• Return on Assets: -4.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 264.81
• Cash Flow: $0.01 per share
• Price / Cash Flow: 8.63
• Book Value: $0.02 per share
• Price / Book: 2.27

Miscellaneous

• Outstanding Shares: 408,290,000
• Free Float: 248,160,000
• Market Cap: $18.54 million
• Optionable: Not Optionable
• Beta: -0.75